奧馬珠單抗

{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 458283563
| type = mab
| image = Omalizumab.png
| caption = 奧馬珠單抗結構：（A）小鼠互補決定區和 （B） IgG1κ 人框架
| alt =

| mab_type = mab
| source = zu/o
| target = IgE

| pronounce = {{IPAc-en|%|oU|m|@|"|l|I|z|u|m|{|b}}

| tradename = Xolair
| Drugs.com =
| MedlinePlus = a603031
| DailyMedID = Omalizumab
| pregnancy_AU = B1
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = 皮下注射
| class =
| ATC_prefix = R03
| ATC_suffix = DX05
| ATC_supplemental =
| biosimilars = Omlyclo

| legal_AU = S4
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = / Schedule D
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment = 。当病因是过敏且其他疗法无效时可使用此藥物。它是一种单克隆抗体，可與免疫球蛋白E（IgE）结合並抑制免疫球蛋白E所引起的後續反應。

奧馬珠單抗于 2003 年及2005在美国及欧洲取得医疗使用許可 。

参考文獻